Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats[J]. Int J Antimicrob Agents, 2006, 27 (Suppl 1): 3-6.
[2]
Chakrabarti A, Chatterjee SS, Rao KL, et al. Recent experience with fungaemia: change in species distribution and azole resistance[J]. Scand J Infect Dis, 2009, 41(4): 275-284.
[3]
Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003[J]. J Clin Microbiol, 2005, 43(4): 1829-1835.
[4]
Castagnola E, Machetti M, Bucci B, et al. Antifungal prophylaxis with azole derivatives[J]. Clin Microbiol Infect, 2004, 10 (Suppl 1): 86-95.
Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance[J]. J Hosp Infect, 2002, 50(4): 243-260.
[7]
Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10. 5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion[J]. J Clin Microbiol, 2010, 48(4): 1366-1377.
[8]
Diekema DJ, Messer SA, Boyken LB, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods[J]. J Clin Microbiol, 2009, 47(10): 3170-3177.
Medeiros EA, Lott TJ, Colombo AL, et al. Evidence for a pseudo-outbreak of Candida guilliermondii fungemia in a university hospital in Brazil[J]. J Clin Microbiol, 2007, 45(3): 942-947.
[12]
Girmenia C, Pizzarelli G, Cristini F, et al. Candida guilliermondii fungemia in patients with hematologic malignancies[J]. J Clin Microbiol, 2006, 44(7): 2458-2464.
[13]
Peman J, Bosch M, Canton E, et al. Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period[J]. Diagn Microbiol Infect Dis, 2008, 60(1): 109-112.
[14]
Miranda LN, van der Heijden IM, Costa SF, et al. Candida colonisation as a source for candidaemia[J]. J Hosp Infect, 2009, 72(1): 9-16.
[15]
Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus[J]. J Clin Microbiol, 2004, 42(10): 4419-4431.
[16]
Pfaller MA, Diekema DJ, Mendez M, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program[J]. J Clin Microbiol, 2006, 44(10): 3551-3556.
[17]
Barchiesi F, Spreghini E, Tomassetti S, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis[J]. Antimicrob Agents Chemother, 2006, 50(8): 2719-2727.
[18]
Canton E, Peman J, Sastre M, et al. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii[J]. Antimicrob Agents Chemother, 2006, 50(8): 2829-2832.
[19]
Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance[J]. J Clin Microbiol, 2008, 46(1): 150-156.
[20]
Savini V, Catavitello C, Di MI, et al. Pan-azole-resistant Candida guilliermondii from a leukemia patient’s silent funguria[J]. Mycopathologia, 2010, 169(6): 457-459.
[21]
Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidulafungin against more than 2, 500 clinical isolates of Candida spp. , including 315 isolates resistant to fluconazole[J]. J Clin Microbiol, 2005, 43(11): 5425-5427.
[22]
Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States[J]. Antimicrob Agents Chemother, 2003, 47(10): 3149-3154.
[23]
Kabbara N, Lacroix C, de Latour RP, et al. Breakthrough C, parapsilosis and C. Guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy[J]. Haematologica, 2008, 93(4): 639-640.
